{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:42:44Z","timestamp":1782783764117,"version":"3.54.5"},"reference-count":105,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation (MEMVIE) programme.","award":["NIHR20411"],"award-info":[{"award-number":["NIHR20411"]}]},{"name":"UK National Institute for Health Research (NIHR) Senior Investigator","award":["NF-SI-0616-10103"],"award-info":[{"award-number":["NF-SI-0616-10103"]}]},{"name":"UK NIHR Applied Research Collaboration Oxford and Thames Valley"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study carried out a systematic literature review of economic evaluations of varicella vaccination programmes from the earliest publication to the present day, including programmes in the workplace and in special risk groups as well as universal childhood vaccination and catch up programmes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Articles published from 1985 until 2022 were sourced from PubMed\/Medline, Embase, Web of Science, NHSEED and Econlit. Eligible economic evaluations, which included posters and conference abstracts, were identified by two reviewers who scrutinised each other\u2019s selections at both title and abstract and full report stages. The studies are described in terms of their methodological characteristics. Their results are aggregated by type of vaccination programme and the nature of the economic outcome.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 2575 articles were identified of which 79 qualified as economic evaluations. A total of 55 studies focused on universal childhood vaccination, 10 on the workplace and 14 on high risk groups. Twenty-seven studies reported estimates of incremental cost per quality-adjusted life year (QALY) gained, 16 reported benefit-cost ratios, 20 reported cost-effectiveness outcomes in terms of incremental cost per event or life saved and 16 reported cost-cost offset results. Most studies of universal childhood vaccination reported an increase in overall costs to health services, but often a reduction in cost from a societal perspective.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The evidence surrounding the cost-effectiveness of varicella vaccination programmes remains sparse with contrasting conclusions in some areas. Future research should particularly aim to encompass the impact of universal childhood vaccination programmes on herpes zoster among adults.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0282327","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T17:23:41Z","timestamp":1679937821000},"page":"e0282327","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systematic review of economic evaluations of varicella vaccination programmes"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-9663","authenticated-orcid":true,"given":"Robert","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5038","authenticated-orcid":true,"given":"Sungwook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"3","key":"pone.0282327.ref001","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"AM Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"pone.0282327.ref002","volume-title":"The Green Book (Chapter 34)","author":"Public Health England","year":"2013"},{"issue":"1","key":"pone.0282327.ref003","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/jmv.10313","article-title":"Epidemiology of varicella-zoster virus in England and Wales","volume":"70","author":"M Brisson","year":"2003","journal-title":"J Med Virol"},{"issue":"13","key":"pone.0282327.ref004","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1017\/S0950268817001649","article-title":"Trends in the burden of varicella in UK general practice","volume":"145","author":"JL Walker","year":"2017","journal-title":"Epidemiol Infect"},{"issue":"42","key":"pone.0282327.ref005","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.42.1900233","article-title":"Burden of varicella complications in secondary care, England, 2004 to 2017","volume":"24","author":"JL Bernal","year":"2019","journal-title":"Euro Surveil"},{"issue":"9","key":"pone.0282327.ref006","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14760584.2020.1825947","article-title":"Varicella vaccination in Italy and Germany\u2014different routes to success: a systematic review","volume":"19","author":"F Kauffmann","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"25","key":"pone.0282327.ref007","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"pone.0282327.ref008","doi-asserted-by":"crossref","first-page":"e20153741","DOI":"10.1542\/peds.2015-3741","article-title":"Global varicella vaccine effectiveness: a meta-analysis","volume":"137","author":"M Marin","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"pone.0282327.ref009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/infdis\/jiq052","article-title":"Effectiveness of 2 doses of varicella vaccine in children","volume":"203","author":"ED Shapiro","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0282327.ref010","volume-title":"Varicella-zoster virus","author":"P Annunziato","year":"2000"},{"key":"pone.0282327.ref011","unstructured":"WHO Introduction of Varicella Vaccination. https:\/\/immunizationdata.who.int\/pages\/vaccine-intro-by-antigen\/varicella.html?ISO_3_CODE=&YEAR=Accessed 7 October 2021"},{"issue":"3","key":"pone.0282327.ref012","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"FH Varela","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pone.0282327.ref013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes: a review of the literature","volume":"21","author":"N Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"pone.0282327.ref014","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14760584.7.6.753","article-title":"Cost-effectiveness of varicella vaccination programs: an update of the literature","volume":"7","author":"MH Rozenbaum","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"pone.0282327.ref015","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.4161\/hv.25228","article-title":"Economic evaluation of varicella vaccination: results of a systematic review","volume":"9","author":"B Unim","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0282327.ref016","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12889-015-1861-8","article-title":"Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries","volume":"15","author":"O Damm","year":"2015","journal-title":"BMC Public Health"},{"key":"pone.0282327.ref017","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"key":"pone.0282327.ref018","unstructured":"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021249206"},{"key":"pone.0282327.ref019","unstructured":"\u2018CCEMG\u2013EPPI-Centre Cost Converter\u2019 (v.1.6 last update: 29 April 2019) https:\/\/eppi.ioe.ac.uk\/costconversion\/default.aspx. Last accessed 30 November 2021."},{"issue":"3","key":"pone.0282327.ref020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/XEB.0000000000000063","article-title":"Conducting systematic reviews of economic evaluations","volume":"13","author":"JS Gomersall","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"pone.0282327.ref021","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"AP Siddaway","year":"2019","journal-title":"Annu Rev Psychol"},{"key":"pone.0282327.ref022","volume-title":"Evidence-based health economics: from effectiveness to efficiency in systematic review","author":"M. Drummond","year":"2002"},{"issue":"2","key":"pone.0282327.ref023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria","volume":"21","author":"S Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"pone.0282327.ref024","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"16","author":"D Husereau","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"pone.0282327.ref025","first-page":"632","article-title":"Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents","volume":"95","author":"TA Lieu","year":"1995","journal-title":"Pediatrics"},{"issue":"27\u201328","key":"pone.0282327.ref026","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.vaccine.2004.03.043","article-title":"An economic evaluation of varicella vaccination in Italian adolescents","volume":"22","author":"N Thiry","year":"2004","journal-title":"Vaccine"},{"issue":"25\u201326","key":"pone.0282327.ref027","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1016\/S0264-410X(03)00405-5","article-title":"Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination","volume":"21","author":"T Hanslik","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"pone.0282327.ref028","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9343(00)00445-9","article-title":"Cost effectiveness of vaccination strategies in adults without a history of chickenpox","volume":"108","author":"KJ Smith","year":"2000","journal-title":"Am J Med"},{"issue":"3","key":"pone.0282327.ref029","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/clinids\/17.3.441","article-title":"An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients","volume":"17","author":"IC Kitai","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0282327.ref030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1399-3046.2001.00032.x","article-title":"Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation","volume":"5","author":"AD Olson","year":"2001","journal-title":"Pediatr Transplant"},{"issue":"1","key":"pone.0282327.ref031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/00365548.2013.847529","article-title":"Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong","volume":"46","author":"KS Chui","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"pone.0282327.ref032","first-page":"01","article-title":"Assessment of the clinical and economic impact of different immunization protocols of measles, mumps, rubella and varicella in internationally adopted children","volume":"8","author":"S Boccalini","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"pone.0282327.ref033","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/j.ijid.2011.06.001","article-title":"Comparison of two strategies to prevent varicella outbreaks in housing facilities for asylum seekers","volume":"15","author":"S de Valliere","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"4","key":"pone.0282327.ref034","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2310\/7060.2003.40545","article-title":"Cost-effectiveness of serotesting compared with universal immunization for varicella in refugee children from six geographic regions","volume":"10","author":"M Figueira","year":"2003","journal-title":"J Travel Med"},{"issue":"8","key":"pone.0282327.ref035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/512673","article-title":"Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis","volume":"44","author":"P Merrett","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4 Pt 1","key":"pone.0282327.ref036","first-page":"535","article-title":"Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles","volume":"92","author":"WJ Smith","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"9","key":"pone.0282327.ref037","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2005.09.028","article-title":"The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles","volume":"24","author":"A Pinot de Moira","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"pone.0282327.ref038","first-page":"519","article-title":"Cost-effectiveness of routine antenatal varicella screening","volume":"91","author":"JC Glantz","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"9","key":"pone.0282327.ref039","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/milmed\/163.9.631","article-title":"A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets","volume":"163","author":"BR Burnham","year":"1998","journal-title":"Mil Med"},{"key":"pone.0282327.ref040","first-page":"3","article-title":"An economic analysis of varicella immunization in the Singapore military","volume":"3","author":"JJ Goh","year":"2016","journal-title":"Mil Med Res"},{"issue":"4","key":"pone.0282327.ref041","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/milmed\/165.4.309","article-title":"The cost-effectiveness of varicella screening and vaccination in U.S. Army recruits","volume":"165","author":"MR Howell","year":"2000","journal-title":"Mil Med"},{"issue":"2","key":"pone.0282327.ref042","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mjafi.2021.06.010","article-title":"Health technology assessment of varicella vaccine in the Armed Forces","volume":"78","author":"S Patrikar","year":"2022","journal-title":"Med J Armed Forces India"},{"issue":"10","key":"pone.0282327.ref043","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ajic.2015.05.027","article-title":"Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel","volume":"43","author":"GJ Baracco","year":"2015","journal-title":"Am J Infect Control"},{"issue":"43","key":"pone.0282327.ref044","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2005.06.004","article-title":"Cost-effectiveness of varicella vaccination of healthcare workers","volume":"23","author":"G Chodick","year":"2005","journal-title":"Vaccine"},{"issue":"24 Suppl 4","key":"pone.0282327.ref045","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/55.suppl_4.S4","article-title":"A cost-effectiveness model for analyzing two varicella vaccination strategies","volume":"55","author":"J. Gayman","year":"1998","journal-title":"Am J Health Sys Pharm"},{"issue":"2","key":"pone.0282327.ref046","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S0950268897007887","article-title":"An economic analysis of varicella vaccination for health care workers","volume":"119","author":"AM Gray","year":"1997","journal-title":"Epidemiol Infect"},{"issue":"7","key":"pone.0282327.ref047","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2307\/30141191","article-title":"Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers","volume":"18","author":"MD Nettleman","year":"1997","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"pone.0282327.ref048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/jhin.2002.1334","article-title":"Varicella and paediatric staff: current practice and vaccine cost-effectiveness","volume":"53","author":"J O\u2019Neill","year":"2003","journal-title":"J Hosp Infect"},{"issue":"11\u201312","key":"pone.0282327.ref049","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0264-410X(02)00431-0","article-title":"The cost-effectiveness of routine childhood varicella vaccination in Germany","volume":"21","author":"K Banz","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"pone.0282327.ref050","doi-asserted-by":"crossref","first-page":"A588","DOI":"10.1016\/j.jval.2015.09.1503","article-title":"Health economic evaluation of different vaccination strategies against varicella and herpes zoster in Germany","volume":"18","author":"O Damm","year":"2015","journal-title":"Value Health"},{"key":"pone.0282327.ref051","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/INF.0000000000003136","article-title":"Health impact and cost-effectiveness assessment for the introduction of universal varicella vaccination in Switzerland","volume":"40","author":"U Heininger","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pone.0282327.ref052","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.vaccine.2012.10.100","article-title":"How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia","volume":"31","author":"A Paternina-Caicedo","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"pone.0282327.ref053","doi-asserted-by":"crossref","first-page":"e0220921","DOI":"10.1371\/journal.pone.0220921","article-title":"Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model","volume":"14","author":"LJ Wolfson","year":"2019","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1","key":"pone.0282327.ref054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"A Melegaro","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"pone.0282327.ref055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jval.2020.10.004","article-title":"What we know now: an economic evaluation of chickenpox vaccination and dose timing using an agent-based model","volume":"24","author":"ERS Rafferty","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"pone.0282327.ref056","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"AJ Van Hoek","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"pone.0282327.ref057","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1080\/21645515.2021.1958608","article-title":"Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model","volume":"17","author":"Q Wang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0282327.ref058","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/ijpvm.IJPVM_295_16","article-title":"Cost-effectiveness of varicella vaccination program in Iran","volume":"8","author":"S Esmaeeli","year":"2017","journal-title":"Int J Prev Med"},{"issue":"11","key":"pone.0282327.ref059","first-page":"e3617","article-title":"Epidemiological impact and costeffectiveness of varicella vaccination strategies in the United Kingdom (UK)","volume":"3","author":"EIH Akpo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0282327.ref060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/INF.0000000000003448","article-title":"Economic evaluation of universal varicella vaccination in Mexico","volume":"41","author":"E Chacon-Cruz","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0282327.ref061","first-page":"1","article-title":"Cost effectiveness and budget impact of universal varicella vaccination in Russia","volume":"8","author":"A Marijam","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"pone.0282327.ref062","doi-asserted-by":"crossref","first-page":"e0254080","DOI":"10.1371\/journal.pone.0254080","article-title":"Clinical and economic impact of universal varicella vaccination in Norway: A modeling study","volume":"16","author":"M Pawaskar","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"pone.0282327.ref063","doi-asserted-by":"crossref","first-page":"A583","DOI":"10.1016\/j.jval.2015.09.1954","article-title":"Pharmacoeconomic evaluation of the introduction of routine varicella vaccination in children in the United Kingdom","volume":"18","author":"K Holl","year":"2015","journal-title":"Value Health"},{"issue":"10","key":"pone.0282327.ref064","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis","volume":"88","author":"M Brisson","year":"2003","journal-title":"Arch Dis Child"},{"issue":"3","key":"pone.0282327.ref065","first-page":"A118","article-title":"Cost-effectiveness analysis of the introduction of the varicellavaccine in Colombia","volume":"14","author":"F De La Hoz","year":"2011","journal-title":"Value Health"},{"issue":"3","key":"pone.0282327.ref066","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/j.jval.2018.09.2524","article-title":"Estimation of the long-term population costs and benefits for five different varicella childhood immunization strategies in Bulgaria","volume":"21","author":"M Dimitrova","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"pone.0282327.ref067","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/infdis\/174.Supplement_3.S335","article-title":"Costs and benefits of routine varicella vaccination in German children","volume":"174","author":"P Beutels","year":"1996","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0282327.ref068","doi-asserted-by":"crossref","first-page":"A357","DOI":"10.1016\/j.jval.2013.08.203","article-title":"Cost-effectiveness of universal vaccination against varicella in the Netherlands","volume":"16","author":"PT De Boer","year":"2013","journal-title":"Value Health"},{"issue":"9","key":"pone.0282327.ref069","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1097\/INF.0000000000001215","article-title":"The cost-effectiveness of varicella zoster virus vaccination considering late onset asthma","volume":"35","author":"J Ditkowsky","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"pone.0282327.ref070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00006454-200206000-00012","article-title":"Instituting a routine varicella vaccination program in Canada: an economic evaluation","volume":"21","author":"D Getsios","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pone.0282327.ref071","first-page":"33","article-title":"Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy","volume":"12","author":"LE Gialloreti","year":"2005","journal-title":"Herpes"},{"issue":"2","key":"pone.0282327.ref072","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0163-4453(03)00079-3","article-title":"Cost containment analysis of childhood vaccination against varicella in Israel","volume":"48","author":"GM Ginsberg","year":"2004","journal-title":"J Infect"},{"issue":"6","key":"pone.0282327.ref073","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0022-3476(05)83173-7","article-title":"Childhood vaccination against chickenpox: an analysis of benefits and costs","volume":"124","author":"DM Huse","year":"1994","journal-title":"J Pediatr"},{"issue":"5","key":"pone.0282327.ref074","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.1994.03510290057037","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"TA Lieu","year":"1994","journal-title":"JAMA"},{"issue":"5","key":"pone.0282327.ref075","first-page":"432","article-title":"A cost-benefit analysis of varicella vaccination in Aragon","volume":"115","author":"G Pena Blasco","year":"2017","journal-title":"Arch Argent Pediatr"},{"issue":"6","key":"pone.0282327.ref076","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0277-9536(99)00115-X","article-title":"The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule","volume":"49","author":"P Scuffham","year":"1999","journal-title":"Soc Sci Med"},{"issue":"5\u20136","key":"pone.0282327.ref077","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0264-410X(99)00261-3","article-title":"The cost-effectiveness of varicella vaccine programs for Australia","volume":"18","author":"PA Scuffham","year":"1999","journal-title":"Vaccine"},{"issue":"12","key":"pone.0282327.ref078","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpedi.159.12.1136","article-title":"Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001","volume":"159","author":"F Zhou","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"pone.0282327.ref079","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1542\/peds.2013-0698","article-title":"Economic evaluation of the routine childhood immunization program in the United States, 2009","volume":"133","author":"F Zhou","year":"2014","journal-title":"Pediatrics"},{"issue":"47\u201348","key":"pone.0282327.ref080","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2006.04.051","article-title":"Economic evaluation of varicella vaccination in Spain: results from a dynamic model","volume":"24","author":"X Lenne","year":"2006","journal-title":"Vaccine"},{"key":"pone.0282327.ref081","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CEOR.S229685","article-title":"The cost-effectiveness of universal varicella vaccination in italy: a model-based assessment of vaccination strategies","volume":"12","author":"C Azzari","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"pone.0282327.ref082","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4161\/hv.23334","article-title":"Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?","volume":"9","author":"J Bilcke","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"pone.0282327.ref083","doi-asserted-by":"crossref","first-page":"A433","DOI":"10.1016\/S1098-3015(10)66461-3","article-title":"Cost-effectiveness of mass vaccination for varicella in France with MMRV versus MMR","volume":"11","author":"K Littlewood","year":"2008","journal-title":"Value Health"},{"issue":"7","key":"pone.0282327.ref084","doi-asserted-by":"crossref","first-page":"A424","DOI":"10.1016\/S1098-3015(10)75097-X","article-title":"Cost-effectiveness of mass varicella vaccination in France: Economic consequences of an intensive vaccination program","volume":"12","author":"KJ Littlewood","year":"2009","journal-title":"Value Health"},{"issue":"7","key":"pone.0282327.ref085","doi-asserted-by":"crossref","first-page":"A393","DOI":"10.1016\/j.jval.2012.08.1113","article-title":"Pharmacoeconomic evaluation of the introduction of universal varicella vaccination in italy","volume":"15","author":"C Sauboin","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"pone.0282327.ref086","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1016\/j.jval.2012.03.060","article-title":"Translating outcomes from a dynamic transmission model for varicella vaccination to cost-effectiveness estimates: The impact of different analytic approaches on the results","volume":"15","author":"JR Thompson","year":"2012","journal-title":"Value Health"},{"issue":"10","key":"pone.0282327.ref087","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ebiom.2015.08.017","article-title":"Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster","volume":"2","author":"A Van Lier","year":"2015","journal-title":"EBioMedicine"},{"issue":"5","key":"pone.0282327.ref088","doi-asserted-by":"crossref","first-page":"e0251644","DOI":"10.1371\/journal.pone.0251644","article-title":"Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model","volume":"16","author":"E Wolff","journal-title":"PLoS One 2021 [Electronic Resource]"},{"issue":"13","key":"pone.0282327.ref089","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00019053-200422130-00003","article-title":"Varicella vaccination in Italy: an economic evaluation of different scenarios","volume":"22","author":"L Coudeville","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"pone.0282327.ref090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/hv.9898","article-title":"Economic evaluation of varicella vaccination in Swiss children and adolescents","volume":"5","author":"K Banz","year":"2009","journal-title":"Hum Vaccin"},{"issue":"44","key":"pone.0282327.ref091","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.vaccine.2008.07.096","article-title":"Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases","volume":"26","author":"P Bonanni","year":"2008","journal-title":"Vaccine"},{"issue":"7\u20138","key":"pone.0282327.ref092","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost-effectiveness of varicella vaccination in Canada","volume":"20","author":"M Brisson","year":"2002","journal-title":"Vaccine"},{"issue":"11\u201312","key":"pone.0282327.ref093","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0264-410X(98)00394-6","article-title":"A cost benefit analysis of routine varicella vaccination in Spain","volume":"17","author":"J Diez Domingo","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"pone.0282327.ref094","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1524-4733.2003.65241.x","article-title":"Validation of health economic models: the example of EVITA","volume":"6","author":"T Hammerschmidt","year":"2003","journal-title":"Value Health"},{"issue":"25\u201326","key":"pone.0282327.ref095","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/S0264-410X(03)00270-6","article-title":"Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives","volume":"21","author":"HC Hsu","year":"2003","journal-title":"Vaccine"},{"issue":"4","key":"pone.0282327.ref096","first-page":"17","article-title":"A benefit-cost analysis of a childhood varicella vaccination programme","volume":"61","author":"SR Preblud","year":"1985","journal-title":"Postgrad Med J"},{"issue":"6","key":"pone.0282327.ref097","first-page":"1450","article-title":"Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan","volume":"36","author":"HF Tseng","year":"2005","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"9","key":"pone.0282327.ref098","doi-asserted-by":"crossref","first-page":"A942","DOI":"10.1016\/j.jval.2017.08.3006","article-title":"The cost-effectiveness of varicella vaccination in Peru","volume":"20","author":"M Blas","year":"2017","journal-title":"Value Health"},{"issue":"6","key":"pone.0282327.ref099","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1098-3015(10)61566-5","article-title":"Childhood vaccination against varicella in France: An economic evaluation of different strategies","volume":"6","author":"L Coudeville","year":"2003","journal-title":"Value Health"},{"issue":"3","key":"pone.0282327.ref100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1524-4733.2005.04005.x","article-title":"The economic value of childhood varicella vaccination in France and Germany","volume":"8","author":"L Coudeville","year":"2005","journal-title":"Value Health"},{"issue":"2","key":"pone.0282327.ref101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(98)00161-3","article-title":"The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France","volume":"17","author":"L Coudeville","year":"1999","journal-title":"Vaccine"},{"issue":"7","key":"pone.0282327.ref102","doi-asserted-by":"crossref","first-page":"A427","DOI":"10.1016\/S1098-3015(10)75110-X","article-title":"Cost estimates in the economic evaluations of vaccination programmes: The cases of rotavirus and varicella in Brazil","volume":"12","author":"J Valentim","year":"2009","journal-title":"Value Health"},{"issue":"49","key":"pone.0282327.ref103","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/j.vaccine.2008.07.021","article-title":"Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil","volume":"26","author":"J Valentim","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"pone.0282327.ref104","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"GD Sanders","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"pone.0282327.ref105","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.vaccine.2021.01.061","article-title":"Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review","volume":"39","author":"B Hodgkinson","year":"2021","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T17:25:23Z","timestamp":1679937923000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282327"}},"subtitle":[],"editor":[{"given":"Matteo","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0282327","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}